Applies to sodium zirconium cyclosilicate: oral powder for suspension.

Side effects include:

Edema, hypokalemia.

For Healthcare Professionals

Applies to sodium zirconium cyclosilicate: oral powder for reconstitution.

General

The most commonly reported adverse reactions reported during clinical trials included edema and hypokalemia.^[Ref]

Cardiovascular

Very common (10% or more): Edema (up to 16.1%)

During clinical trials, edema was reported in 4.4% of patients receiving 5 g/day, 5.9% of patients receiving 10 g/day and 16.1% of patients receiving 15 g/day for up to 28 days (placebo 2.4%). In longer-term trials, 8% to 11% of patients receiving doses less than 15 g/day reported edema, generalized edema and peripheral edema.

Metabolic

Common (1% to 10%): Hypokalemia

Frequency not reported: Increase in sodium bicarbonate concentrations

In clinical trials, 4.1% of patients developed hypokalemia which resolved with dose reduction or discontinuation.

Small, dose-dependent increases in sodium bicarbonate occurred with once daily dosing (1.1 mmol/L at 5 g/day; 2.3 mmol/L at 10 g/day; 2.6 mmol/L at 15 g/day; 0.6 mmol/L in placebo). The clinical significance of this is unknown.